Senores Pharmaceuticals Ltd

{"actualRevenue":1751900000,"estimateRevenue":1938000000,"revenueSurprise":-186100000,"revenueSurprisePercent":-9.602683178534571,"actualEPS":7.96,"estimateEPS":7.1196,"surprise":0.8403999999999998,"surprisePercent":11.8040339344907}

{"description":"Senores Pharmaceuticals expects to exceed its FY26 growth target, anticipating revenue from emerging markets to reach ₹150 crore this year and ₹180-200 crore next year. The company reported a 69.4% revenue increase in Q3FY26, with profit more than doubling.","url":"https://www.cnbctv18.com/market/earnings/senores-pharma-expects-to-beat-fy26-growth-target-md-swapnil-shah-19825565.htm","sentiment":"Positive","domain":"CNBCTV18"}

{"description":"Senores Pharmaceuticals anticipates significant revenue growth following its acquisition of Apnar Pharma, projecting ₹250 crore by FY28. The deal includes five ANDAs with a market potential of $700 million, enhancing their US manufacturing capabilities.","url":"https://www.cnbctv18.com/business/companies/senores-pharma-strong-growth-apnar-deal-revenue-projection-fy28-19793903.htm","sentiment":"Positive","domain":"CNBCTV18"}

{"description":"Senores Pharmaceuticals is identified as a strong growth stock for Diwali, focusing on US and Canada markets with USFDA-approved facilities. Recent product approvals may boost revenue from H2FY26, aiming for an EBITDA margin rise from 22.5% in FY25 to 25% in FY26.","url":"https://www.cnbctv18.com/webstories/market/diwali-stock-pick-senores-pharma-poised-for-strong-growth-22496.htm","sentiment":"Positive","domain":"CNBCTV18"}